|
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
|
2R01CA173481-06
|
$385,883
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
3UM1CA186704-04S1
|
$170,500
|
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
Postmenopausal women's alcohol study
|
ZIA CP000101 10336
|
$951
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
Frederick repository and lab support
|
ZIA CP000112 10313
|
$61,784
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Case-Control Study
|
ZIA CP000185 10318
|
$63,563
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
The Golestan Cohort Study
|
ZIA CP000185 10361
|
$65,336
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
Nanoparticle mediated microenvironmental targeting of CCL3 signaling for the treatment of acute myelogenous leukemia
|
1F31CA228391-01
|
$42,418
|
|
ACKUN-FARMMER, MARIAN
|
UNIVERSITY OF ROCHESTER
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Genetics of Graft-versus-Host Disease
|
1R01CA231141-01
|
$265,229
|
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems
|
1R01CA227136-01A1
|
$454,956
|
|
AGHI, MANISH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
5K08CA218420-02
|
$177,120
|
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
Mutagenesis and migration in glioblastoma cells
|
1R21CA220111-01A1
|
$179,240
|
|
AHN, EUN HYUN
|
UNIVERSITY OF WASHINGTON
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
|
5F30CA220847-02
|
$49,524
|
|
ALI, MOIEZ
|
DUKE UNIVERSITY
|
|
Profiling signaling activity and gene expression in single, pancreatic adenocarcinoma cells using CE-RNA-Seq
|
1R01CA224763-01A1
|
$575,272
|
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
|
7R01CA182076-05
|
$339,622
|
|
ALLEN, PETER
|
DUKE UNIVERSITY
|
|
Oncohistones: Role of Histone H3 Mutations in the Oncogenesis of Pediatric Cancers
|
5P01CA196539-04
|
$1,855,117
|
|
ALLIS, CHARLES
|
ROCKEFELLER UNIVERSITY
|
|
Therapeutic resistance in leukemic cells: targeting BCL-2 family and autophagy
|
5R01CA184137-04
|
$362,569
|
|
ALMASAN, ALEXANDRU
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
5U01CA202144-04
|
$741,952
|
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Novel Molecular Therapies of Prostate Cancer
|
5P01CA140043-09
|
$1,222,825
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Tumor Plasticity
|
5R35CA220446-02
|
$1,140,000
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
3R01CA208042-03S1
|
$223,893
|
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-05
|
$307,736
|
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-04
|
$701,778
|
$14,036
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The regulation of dendritic cell function by LMYC at steady state and during immune responses to cancer
|
1F31CA228240-01
|
$30,442
|
|
ANDERSON, DAVID
|
WASHINGTON UNIVERSITY
|
|
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
|
1U01CA232382-01
|
$688,043
|
|
ANDERSON, ALEXANDER
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Performance, safety, and efficacy of a new cyrotherapy device for cervical dyspla
|
5UH3CA189923-05
|
$762,683
|
|
ANDERSON, JEAN
|
JOHNS HOPKINS UNIVERSITY
|
|
General Descriptive Studies
|
ZIA CP010183 00350
|
$1,090,047
|
|
Anderson, William
|
DCEG (NCI)
|
|
Defining the Transcriptional Regulation and Genomic Organization of FAIM3 and PIGR, Human Ig Receptors Involved in Immunity, Auto-Immune Disease, and Lymphoma
|
5F31CA221012-02
|
$30,434
|
|
ANDREWS, JARED
|
WASHINGTON UNIVERSITY
|
|
Cancer Metabolism Training Program
|
1T32CA221709-01A1
|
$201,444
|
|
ANN, DAVID
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Clinical Validation of the Multiple Biopsy Device, a Novel Endoscopic Biopsy Technology
|
1R43CA228656-01
|
$206,274
|
|
APPLING, ANTHONY
|
ENDOSCOPIC ASSIST DEVICES, LLC
|
|
Cancer Genetics of Short Telomere Syndromes
|
1R01CA225027-01A1
|
$530,521
|
|
ARMANIOS, MARY
|
JOHNS HOPKINS UNIVERSITY
|
|
Research Training in Pediatric Oncology
|
5T32CA136432-10
|
$491,462
|
|
ARMSTRONG, SCOTT
|
DANA-FARBER CANCER INST
|
|
Predicting the Presence of Clinically Significant Prostate Cancer using Multiparametric MRI and MR-US Fusion Biopsy
|
1R21CA220352-01A1
|
$195,568
|
|
ARNOLD, COREY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132384-09
|
$1,192,031
|
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
Reversing Cellular immortality in cancer
|
5R35CA197563-04
|
$962,915
|
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Role of HER2 mutations in breast cancer progression and response to targeted therapies
|
1R01CA224899-01A1
|
$382,641
|
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-08S1
|
$175,000
|
$3,500
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-08
|
$2,480,000
|
$49,600
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Dual Targeting Redox?active Gold(I) Therapeutics
|
1R15CA232765-01
|
$462,195
|
|
ARUMUGAM, KUPPUSWAMY
|
WRIGHT STATE UNIVERSITY
|
|
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications
|
1R01CA230516-01
|
$564,655
|
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S9
|
$6,765,398
|
$67,654
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SA
|
$124,999
|
$1,250
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SB
|
$59,999
|
$600
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles
|
1R43CA232778-01
|
$295,240
|
|
ASSOULINE, JOE
|
NANOMEDTRIX, LLC
|
|
Cone Beam Tomosynthesis Fluoroscopy for Image Guided Interventions
|
3R43CA228158-01A1S1
|
$50,000
|
|
ATRIA, CRISTIAN
|
NVIEW MEDICAL, INC.
|
|
Genetic and Dietary Interactions in MMR Deficient Colon Tumorigenesis
|
1R01CA222358-01A1
|
$635,306
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
Total relevant funding to Eye for this search: $9,033,014
|